Novartis CEO says remibrutinib could become one of its largest medicines
AI Summary- Novartis CEO Vas Narasimhan said remibrutinib could become a major medicine for the company.
- Late-stage multiple sclerosis trial results reached the primary endpoint but appeared weaker than expected.
- Novartis reported improved third-quarter profitability while emerging from its steepest patent cliff.